ABIVAX Société Anonyme (0RA9.L)

7.05 +0.09 (+1.30%) At close: 03:13PM BST

ABIVAX Société Anonyme

5, rue de la Baume
Paris 75008
France
33 1 53 83 08 41
https://www.abivax.com

Sector(s): 
Industry: 
Full-time employees: 24

Key executives

Name	Title	Pay	Exercised	Year born
Prof. Hartmut J. Ehrlich	Chief Exec. Officer	456.81k	N/A	N/A
Dr. Philippe Pouletty M.D., Ph.D.	Founder & Director	N/A	N/A	1958
Mr. Didier Blondel	EVP, CFO & Board Sec.	N/A	N/A	N/A
Ms. Raquel Lizarraga	Investor Relations Mang.	N/A	N/A	N/A
Ms. Regina Jehle	VP Communications	N/A	N/A	N/A
Anne Pascard	HR Mang.	N/A	N/A	N/A
Mr. Pierre Courteille M.B.A.	Chief Commercial Officer & VP of Bus. Devel.	N/A	N/A	N/A
Mr. Paul Gineste	VP Clinical Operations	N/A	N/A	N/A
Mr. Alain Chevallier	Sr. Advisor	N/A	N/A	1953

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Corporate governance

ABIVAX Société Anonyme’s ISS governance QualityScore as of 1 February 2023 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.